A plant-derived recombinant human glucocerebrosidase enzyme - A preclinical and phase I investigation

Keyphrases

• Recombinant Human 100%
• Plant-derived 100%
• Human Glucocerebrosidase 100%
• Glucocerebrosidase 100%
• Monkey 50%
• Plant Cells 50%
• Primates 50%
• Pharmacokinetics 50%
• Recombinant 50%
• Mammalian Cells 50%
• Neutralizing Antibodies 50%
• Transformed Plants 50%
• Immunogenicity 50%
• High Dose 50%
• Healthy Volunteers 50%
• Cell Systems 50%
• Pharmacokinetic Profile 50%
• Human Subjects 50%
• FDA-approved Drugs 50%
• Copyright 50%
• Intravenous Infusion 50%
• Multiple Organs 50%
• Gaucher Disease 50%
• Lysosomal Storage Disease 50%
• Clinical Drugs 50%
• Drug Adverse Events 50%
• Phase III Clinical Trial 50%
• Enzyme Replacement Therapy 50%
• Phase I Clinical Trial 50%
• Prolonged Half-life 50%
• Imiglucerase 50%
• Treatment Standards 50%
• Repeated Injection 50%
• Commercial Enzymes 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Glucosylceramidase 100%
• Clinical Trial 66%
• Pharmacokinetics 66%
• Neutralizing Antibody 33%
• Adverse Event 33%
• Immunogenicity 33%
• Normal Human 33%
• Haplorhini 33%
• Gaucher's Disease 33%
• Human 33%
• Storage Disease 33%
• Recombinant 33%
• Lysosome Storage Disease 33%
• Imiglucerase 33%